Pivotal study results with the Rezum Radiofrequency System in Benign Prostatic Hyperplasia published in The Journal of Urology- NxThera

NxThera has announced the digital publication of the one-year data from the Rezum II pivotal study of the Rezum Radiofrequency System in The Journal of Urology. The Rezum II clinical study enrolled 197 patients in this randomized, controlled trial across 15 centers in the United States and documents the sustained symptom reduction and preserved sexual function in patients who underwent the Rezum treatment. Using radiofrequency energy to create sterile water vapor (steam) to convectively deliver precise thermal energy treatments, the Rezum System is successful in treating Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH). Key published findings of the study include: *Significant reduction in urinary symptom scores as measured by the International Prostate Symptom Score (IPSS) at two weeks; *IPSS improvement of 11.3 points at three months, which sustained throughout 12 months; *For patients with a baseline IPSS more than 19; mean IPSS improvement was 13.5 points at 1 year; *Peak urinary flow rate increase of 6.3 ml/sec at three months, with sustained improvement throughout 12 months; *Mild to moderate adverse effects that typically resolved within a few weeks; *Preservation of erectile and ejaculatory functions.